<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>ALICLEN - salicylic acid  shampoo </strong><br>Prasco Laboratories<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Aliclen™ (6% w/w Salicylic Acid) Shampoo</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="50744-2">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only <br>FOR DERMATOLOGICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.</span></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION <br></span>Aliclen Shampoo contains 6% w/w salicylic acid USP in a vehicle consisting of purified water USP, acrylates copolymer, edetate disodium USP, lauramide DEA, sodium chloride USP, triethanolamine lauryl sulfate, trolamine, fragrance. <br><br>Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following structure:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=729fba61-cc44-4110-85bd-4743161dc6c0&amp;name=structure.jpg"></p>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY <br></span>Salicylic acid has been shown to produce <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. <br><br>In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 ml). <br><br>Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or diuretics have higher salicylate levels than those with a normal extracellular space. (See <span class="Bold">PRECAUTIONS</span>) <br><br>The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space. <br><br>Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs; by similar competitive mechanisms other drugs can influence the serum levels of salicylate. (See <span class="Bold">PRECAUTIONS</span>)<span class="Bold"> </span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS AND USAGE <br></span>For Dermatologic Use: Aliclen Shampoo is a topical aid in the removal of excessive keratin in hyperkeratotic <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span>, including verrucae, and the various ichthyoses (vulgaris, sexlinked and lamellar), <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">keratosis</span> palmaris and plantaris, <span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">keratosis pilaris</span>, pityriasis rubra pilaris, and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (including body, scalp, palms and soles). </p>
<p>For Podiatric Use: Aliclen Shampoo is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS <br></span>Aliclen Shampoo should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. Aliclen Shampoo should not be used in children under 2 years of age.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">WARNINGS <br></span>Prolonged use over large areas, especially in children and those patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> could result in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>. Excessive application of the product other than is needed to cover the affected area will not result in a more therapeutic benefit. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of hearing, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span>. In the event of salicylic acid toxicity, the use of Aliclen should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal, antiinflammatory agent that is not salicylate based. <br><br>Due to potential risk of developing Reye’s syndrome, salicylate products should not be used in children and teenagers with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, unless directed by a physician.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<span class="Bold">PRECAUTIONS </span><br>For external use only. Avoid contact with eyes and other mucous membranes. <br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">DRUG INTERACTIONS <br></span>The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of Aliclen is not known. <br><br>I. Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:</p>
<a name="id0aef8d1-17cb-4c4d-8864-dd3ad6bfc92f"></a><table border="0" cellpadding="0" cellspacing="0" width="643">
<col width="145">
<col width="498">
<tbody class="Headless">
<tr class="First">
<td>DRUG</td>
<td>DESCRIPTION OF INTERACTION<span> </span>
</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> potentiated.</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Decreases tubular reabsorption;
  clinical toxicity from methotrexate can result.</td>
</tr>
<tr class="Last">
<td>Oral
  Anticoagulants</td>
<td>Increased<span>  </span><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</td>
</tr>
</tbody>
</table>II. Drugs changing salicylate levels by altering renal tubular reabsorption:<br><a name="i56453ed0-da76-4d3d-8059-623614cfa674"></a><table border="0" cellpadding="0" cellspacing="0" width="676">
<col width="140">
<col width="536">
<tbody class="Headless">
<tr class="First">
<td>DRUG</td>
<td>DESCRIPTION OF INTERACTION<span> </span>
</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Decreases plasma salicylate
  level; tapering doses of steroids may promote <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>.</td>
</tr>
<tr>
<td>Acidifying
  Agents</td>
<td>Increases plasma salicylate
  level.</td>
</tr>
<tr class="Last">
<td>Alkanizing
  Agents<span> </span>
</td>
<td>Decreased plasma salicylate
  levels.</td>
</tr>
</tbody>
</table>
<br>III. Drugs with complicated interactions <br>with salicylates:<br><a name="ie7341d57-d944-4a8d-8321-7d0e33b410dd"></a><table border="0" cellpadding="0" cellspacing="0" width="770">
<col width="129">
<col width="641">
<tbody class="Headless">
<tr class="First">
<td>DRUG</td>
<td>DESCRIPTION OF INTERACTION<span> </span>
</td>
</tr>
<tr>
<td>Heparin<span>  </span>
</td>
<td>Salicylate decreases platelet
  adhesiveness and interferes with hemostasis in heparin treated patients.</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Inhibits pyrazinamide-induced
  <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.<span>  </span>
</td>
</tr>
<tr class="Last">
<td>Uricosuric
  Agents<span> </span>
</td>
<td>Effect of probenemide,
  sulfinpyrazone and phenylbutazone inhibited.</td>
</tr>
</tbody>
</table>The following alterations of laboratory tests have been reported during salicylate therapy: <br><a name="id5ebb967-6b6a-468d-8ea2-7c438c0f4fb1"></a><table border="0" cellpadding="0" cellspacing="0" width="676">
<col width="217">
<col width="459">
<tbody class="Headless">
<tr class="First">
<td>LABORATORY
  TESTS<span> </span>
</td>
<td>EFFECT OF<span>  </span>SALICYLATES<span> </span>
</td>
</tr>
<tr>
<td>Thyroid
  Function</td>
<td>Decreased PBI;<span>  </span>increased T3 uptake.<span> </span>
</td>
</tr>
<tr>
<td>Urinary
  Sugar</td>
<td>False negative with glucose
  oxidase; false positive with Clinitest with high-dose salicylate therapy
  (2-5g q.d.).</td>
</tr>
<tr>
<td>5-Hydroxyindole
  acetic acid</td>
<td>False negative with fluorometric
  test.</td>
</tr>
<tr>
<td>Acetone,
  <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketone bodies</span></td>
<td>False positive FeCl3 in Gerhardt
  reaction; red color persists with boiling.</td>
</tr>
<tr>
<td>17-OH
  corticosteroids<span> </span>
</td>
<td>False reduced values with
  &gt;4.8g q.d. salicylate.</td>
</tr>
<tr>
<td>Vanilmandelic
  acid</td>
<td>False reduced values.<span> </span>
</td>
</tr>
<tr>
<td>Uric
  acid</td>
<td>May increase or decrease
  depending on dose.</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span></td>
<td>Decreased levels; slightly
  increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</td>
</tr>
</tbody>
</table>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">Pregnancy (Category C): </span>Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. Aliclen Shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers: </span>Because of the potential for serious adverse reactions in nursing infants from the mother’s use of Aliclen Shampoo, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be used on the chest area to avoid the accidental contamination of the child.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility: <br></span>No data are available concerning potential carcinogenic or reproductive effects of Aliclen Shampoo. Salicylic acid has been shown to lack mutagenic potential in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> test.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS <br></span>Excessive <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and scaling conceivably could result from use on open <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">OVERDOSAGE </span><br>See<span class="Bold"> WARNINGS.</span><br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND <br>ADMINISTRATION </span><br>Wet hair and apply Aliclen Shampoo to the scalp. Work into a lather then rinse. Repeat the treatment as needed until the condition clears. Once clearing is apparent, the occasional use of Aliclen Shampoo will usually maintain the remission.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED </span><br>Aliclen™ Shampoo is available in 177 mL plastic bottles (NDC 66993-887-71). </p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-16"></a><p></p>
<p class="First">Store at controlled room temperature 20°-25°C (68°-77°F). Do not freeze. <br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First">Manufactured for: <br><span class="Bold">Prasco Laboratories</span><br>Mason, OH 45040 USA <br><br>Manufactured by: <br>Groupe Parima Inc. <br>Montreal, QC H4S 1X6 CANADA</p>
<p><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=729fba61-cc44-4110-85bd-4743161dc6c0&amp;name=label.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALICLEN 		
					</strong><br><span class="contentTableReg">salicylic acid shampoo</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66993-887</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SALICYLIC ACID </strong> (SALICYLIC ACID) </td>
<td class="formItem">SALICYLIC ACID </td>
<td class="formItem">60 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER COPOLYMER TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM </strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LAURIC DIETHANOLAMIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROLAMINE LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TROLAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66993-887-71</td>
<td class="formItem">177 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">02/02/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Prasco Laboratories
							(065969375)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Groupe PARIMA, Inc. (252437850)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Groupe PARIMA, Inc.</td>
<td class="formItem"></td>
<td class="formItem">252437850</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>64aa4b2e-75f5-4960-bdc3-e7beab8ebede</div>
<div>Set id: 729fba61-cc44-4110-85bd-4743161dc6c0</div>
<div>Version: 1</div>
<div>Effective Time: 20110202</div>
</div>
</div> <div class="DistributorName">Prasco Laboratories</div></p>
</body></html>
